HSP90 inhibitors for IPF/COVID-19

Subjects: Biochemistry
Contributors: Ruben Manuel Luciano Colunga Biancatelli, Pavel Solopov, John Catravas
Submitted by: Ruben Manuel Luciano Colunga Biancatelli

Definition
Heat shock protein 90 (HSP90) is an important chaperone that assists the late stage folding of several proteins involved in cell survival in response to environmental stressors. The inhibition of HSP90 is followed by a complex modulation of the proteome and the kinome, that has proved beneficial in cancer and various neurodegenerative diseases. Additionally, accumulating literature suggests that HSP90 may be a key target during the development of pulmonary fibrosis and that its inhibition could serve as a new and exciting therapeutic approach. We have summarized the current evidence about HSP90’s role in Idiopathic Pulmonary Fibrosis (IPF), the results from preclinical studies on its inhibition and the intracellular signaling pathways involved, in a recent review article (Review). In this Article entry, we will introduce the main findings discussed in the review and focus on its translation and possible significance in the era of the SARS-CoV-2 pandemic.

Table of Contents [Hide]

1. HSP90 functions and isoforms
HSP90 is a highly expressed and conserved chaperone, described in diverse isoforms (e.g. α, β, mitochondrial), whose activity is necessary for the proper folding of many client proteins. Different isoform of HSP90 can assemble in heterogeneous or homologous dimers (HSP90αα, HSP90ββ or HSP90αβ), with specific chaperone profiles and affinity for protein partners. Few studies have characterized both α and β isoforms behavior during the fibrotic process. HSP90β has shown specific tubulin and microtubule-interacting properties playing a role in cell motility, migration and structural cell stability. HSP90α expression is modulated by Signal Transducer and Activator of Transcription 1 (STAT1) and is involved in cell survival by modulating the caspase 3-depending apoptotic pathway. However, more data is required for a better understanding of HSP90 isoforms, especially in order to develop inhibitors with lower or higher affinity.

2. HSP90 directs myofibroblast differentiation
Fibroblasts represent the central mediators of the fibrotic process as they promote cellular proliferation and deposition of extracellular matrix (ECM) in response to prolonged tissue injury and chronic inflammation. Transforming growth factor-β (TGF-β) is the most important mediator of fibrogenesis, which upregulates and activates fibroblast phenotype and function, inducing fibroblast transdifferentiation. TGF-β signaling is mediated by a complex subset of intracellular mediators divided into the non-Smad- and Smad-dependent signaling pathways. HSP90 stabilizes the TGF-β receptor, modulates its signaling cascades and, similarly to TGF-β, directs myofibroblast differentiation.

Samples taken from patients with IPF revealed the presence of both HSP90α and HSP90β in the pulmonary interstitial tissue, whose expression was increased in areas rich in myofibroblasts and fibroblasts. These fibroblasts localized HSP90 mainly in the nucleus and cytosol, and when treated with HSP90 inhibitors, displayed impaired proliferation, migration and differentiation. Indeed, HSP90 administration increased the production of collagen by fibroblasts and the expression of α-Smooth Muscle Actin (α-SMA) by epithelial cells. Thus, HSP90 promotes epithelial-to-mesenchymal transformation (EMT) of epithelial cells and differentiation of fibroblast into myofibroblasts, whereas its inhibition limits the expression of the aggressive phenotype of IPF fibroblasts.
Proteomic profiling plays an important role in biomarker discovery. Proteomic analyses in IPF have been done on peripheral blood, bronchoalveolar lavage fluid (BALF) and lung tissue. While HSP90β-1 was found increased in peripheral blood of patients with IPF [12], both HSP90α and HSP90β were found increased in lung tissue [13][14]. HSP90 exerts distinct roles when expressed intracellularly, intranuclearly or released into the vascular compartment. Indeed, intracellular HSP90 acts as a chaperone, assisting the maturation, correcting the folding and when irreversibly damaged, promoting the degradation of several client proteins [15]. Differently, HSP90 can be released extracellularly in conditions of stress, promoting Antigen Presenting Cells (APC) maturation and, acting as “alarmins”, triggers the immune system response [16].

Thus, IPF displays high levels of HSP90 both intra- and extra-cellularly, which are required for both the augmented intracellular signaling -and subsequent elevated chaperone activity- and for the activation of the immune system in response to the chronic inflammation in the lung.

HSP90 inhibitors modulate and reduce protein trafficking, restore proteostasis and diminish HSP90 chaperone activity, thus blocking the fibrotic process [17]. The number of HSP90 inhibitors has dramatically increased since the first molecule described in 1994 [18]. Geldanamycin is a natural product and a member of the benzoquinone annamycin family that has demonstrated anti-tumor and anti-proliferative characteristics, whose clinical implementation, however, was limited due to liver toxicity [19][20]. 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) is an analog of geldanamycin with higher affinity for the ATP binding site of HSP90, and lower toxicity [21]. This inhibitor attenuated fibroblast activation and, also, fibroblast to myofibroblast transformation [11]. 17-AAG and 17-DMAG modulate ARAF, AKT, CDK4, MET, and PDK1 affecting principally protein kinase activity, as 34% of kinases are reduced and only 6% of them are upregulated [22]. Another HSP90 inhibitor, 1G6-D7, attenuated the severity of the fibrotic process in a murine model of bleomycin-induced pulmonary fibrosis by downregulating the levels of HSP90 [23].

AUY922, a second generation HSP90 inhibitor, successfully inhibits both isoforms of HSP90 (HSP90α and HSP90β) [24]. Our previous studies on AUY-922 have demonstrated its ability to depress phosphorylation of ERK, interfere with TGF-β signaling, and thereby, prevent the upregulation of ECM in Hydrochloric acid (HCl)- and nitrogen mustard (NM)-induced pulmonary fibrosis [25][26][27]. Dose and effects of various HSP90 inhibitors in in vivo models of pulmonary fibrosis are summarized in table 1 (Table 1). HSP90 inhibitors regulate TGF-β receptor stabilization, interfere with Smad and non-Smad (Raf, P-ERK) TGF-β signaling cascade, downregulate transcription factors, decrease EMT and reduce the production of pro-fibrotic mediators and ECM.

<table>
<thead>
<tr>
<th>Study</th>
<th>Species</th>
<th>Etiology</th>
<th>HSP90 inhibitor</th>
<th>Dose</th>
<th>Time of administration</th>
<th>Dowregulated proteins</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sontake et al. [11]</td>
<td>mice</td>
<td>Bleomycin</td>
<td>17-AAG</td>
<td>15 mg/Kg</td>
<td>1x/day for 3 weeks</td>
<td>Hydroxyproline, α-SMA, Ki67</td>
</tr>
<tr>
<td>Sibinska et al. [13]</td>
<td>mice</td>
<td>Bleomycin</td>
<td>17-DMAG</td>
<td>10 mg/Kg</td>
<td>1 every 2 days for 2 weeks</td>
<td>Collagen I, TGF-β, α-SMA</td>
</tr>
<tr>
<td>Dong et al. [22]</td>
<td>mice</td>
<td>Bleomycin</td>
<td>1G6-D7</td>
<td>1 mg/Kg</td>
<td>1x/day for 3 weeks</td>
<td>HSP90α, IL-6, IL-4, Collagen I, Fibronectin, pERK, pAKT, p-p38</td>
</tr>
<tr>
<td>Marinova et al. [25]</td>
<td>mice</td>
<td>Hydrochloric acid</td>
<td>AUY-922</td>
<td>1 mg/Kg</td>
<td>2x/week for 2 weeks</td>
<td>pHSP90, TGF-β, pERK, Collagen I, Hydroxyproline, Fibronectin</td>
</tr>
</tbody>
</table>

3. HSP90 signaling in IPF proteomic studies

4. HSP90 inhibitors

Table 1. HSP90 inhibitors in in vivo studies on Pulmonary Fibrosis.
<table>
<thead>
<tr>
<th>Solopov et al. [22]</th>
<th><em>mice</em></th>
<th>Hydrochloric acid</th>
<th>AUY-922</th>
<th>1 mg/Kg</th>
<th>2x/week for 4 weeks</th>
<th>pHSP90, TGFβ, pERK, Collagen I, Fibronectin</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>mice</em></td>
<td>nitrogen mustard</td>
<td>AUY-922</td>
<td>1 mg/Kg</td>
<td>2x/week for 10 days</td>
<td>No significant changes</td>
<td></td>
</tr>
<tr>
<td><em>mice</em></td>
<td>nitrogen mustard</td>
<td>AUY-922</td>
<td>1 mg/Kg</td>
<td>2x/week for 30 days</td>
<td>pHSP90, pERK, Collagen I, Fibronectin, Elastin</td>
<td></td>
</tr>
<tr>
<td><em>mice</em></td>
<td>nitrogen mustard</td>
<td>AUY-922</td>
<td>2 mg/Kg</td>
<td>3x/week for 30 days</td>
<td>pHSP90, pERK, Collagen I, Fibronectin, Elastin</td>
<td></td>
</tr>
</tbody>
</table>


### 5. HSP90 inhibition modulates the fibrotic process

HSP90 stabilizes Transforming Growth Factor-β (TGF-β) receptor [28], guarantee its proper signaling via Smad and non-Smad dependent pathways [29][30] and promote collagen secretion via interaction with cytosolic components of the secretory pathway [31]. HSP90 inhibition reduces ERK levels, involved in the non-Smad downstream of TGF-β [23][27], blocks TGF-β induced Smad phosphorylation [32] and lowers circulating levels of HSP90α [23] (Figure 1). HSP90 inhibitors modulate the expression of the proteome (119 peptides) [33] and the kinome (144 kinases) [34] preventing epithelial-to-mesenchymal transformation (EMT) and reducing the production of pro-fibrotic mediators and ECM. HSP90 inhibitors then, modulating the "HSPome", not only block the crucial intracellular signaling of TGF-β, but also modulate the inflammatory markers (via extracellular HSP90) related to IPF.

![Figure 1. Schematic representation of HSP90 involvement in TGF-β signaling cascade. HSP90 plays a crucial role at various levels of the pathogenic pathway of IPF. It stabilizes TGF-β receptor, negatively](image-url)
regulates Raf, preserve ERK from degradation with its binding with HSP90-CDC37 complex and modulates nuclear localization of phospho-Smad4.

6. The need for new antifibrotic therapies in the era of SARS-CoV-2 Pandemic

Pirfenidone and Nintedanib are currently the only FDA approved drugs for IPF; their effect is limited to slowing disease progression \(^{[33]}\) and, as of today, a cure is still missing. Furthermore, as several studies have reported increasing trends in mortality in IPF patients during the last years \(^{[36]}[37]\), the developing new therapeutical targets is still an unmet medical need. HSP90 inhibitors that are already in clinical trials for cancer, despite the promising results in animal models, require further experimentation for the definition of the optimal dosage and related safety in IPF.

Now more than ever, the development of new antifibrotic treatments, appears imperative because of the potential use in preventing the long-term complications from SARS-CoV-2 related disease (COVID-19). Indeed, COVID-19, similarly to ARDS, provokes long-lasting effects on the lung parenchyma and structure that can result in pleural thickening, atelectasis and pulmonary fibrosis \(^{[38]}[39]\), that, in patients with Middle-East Respiratory Syndrome (MERS), directly correlates with disease severity and Intensive Care Unit (ICU) length of stay \(^{[40]}\). It was recently proposed to initiate early antifibrotic therapies for COVID-19 patients with or without IPF \(^{[41]}\). Indeed, blocking TGF-β has been already suggested \(^{[42]}[43]\) since TGF-β is increased in lung sections of patients with COVID-19 \(^{[44]}\). Therefore, HSP90 inhibitors, capable of modulating the downstream cascades of TGF-β, have a strong translating potential for the treatment of COVID-19 patients; clearly, more preclinical and clinical studies are needed.

While few trials are under way to test the effectiveness of Pirfenidone and Nintedanib for the treatment of COVID-19 (NCT04282902, NCT04338802), even more need to focus on the development of new antifibrotic interventions with better efficacy.

7. Conclusion

In this Article Entry we briefly introduced the most significant results of HSP90 inhibition and modulation of the Proteome as potential therapies against the development of pulmonary fibrosis. We then translated their significance to the era of the SARS-CoV-2 pandemic.

References

2. Kim Pepin; Fumitaka Momose; Nobushige Ishida; Kyoosuke Nagata; Molecular Cloning of Horse Hsp90 cDNA and Its Comparative Analysis with Other Vertebrate Hsp90 Sequences. *Journal of Veterinary Medical Science* 2000, 63, 115-124, 10.1292/jvms.63.115.
4. Pierre-Simon Bellaye; Chiko Shimbori; Toyoshi Yanagihara; David Carlson; Philip Hughes; Chandak Upagupta; Seidai Sato; Nolan Wheildon; Timothy Haystead; Kjetil Ask; et al. Martin Rj Kolb Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in lung fibrosis. *European Respiratory Journal* 2018, 51, 1700386, 10.1183/13993003.00386-2017.
Pulmonary Fibrosis in Mice exposure of mice to HCl. treatment with a heat shock protein 90 inhibitor prevents chronic lung injury and pulmonary fibrosis, following acute exposure of mice to HCl. Experimental Lung Research 2020, 46, 203-216, 10.1080/01902148.2020.1764148.


29. Jeeyong Lee; You Sun An; Mi-Ra Kim; Ye-Ah Kim; Jin Kyung Lee; Chang Sun Hwang; Eunkyoung Chung; In-Chul Park; Jae Youn Yi; Heat Shock Protein 90 Regulates Subcellular Localization of Smads in Mv1Lu Cells. *Journal of Cellular Biochemistry* **2015**, *117*, 230-238, 10.1002/jcb.25269.


33. Dongweon Song; Rathgothama Chaerkady; Aik-Choon Tan; Elena García-García; Anuradha Nalli; Ana Suarez-Gauthier; Fernando Lopez-Rios; Xian Feng Zhang; Anna Solomon; Jeffrey Tong; et al.Margaret ReadChristian FritzAntonio JimenoAkhhilesh PandeyManuel Hidalgo Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. *Molecular Cancer Therapeutics* **2008**, *7*, 3275-3284, 10.1158/1535-7163.mct-08-0508.

34. Armin Haupt; Gerard Joberty; Marcus Bantscheff; Holger Fröhlich; Henning Stehr; Michael-Ruth Schweiger; Axel Fischer; Martin Kerick; Stefan Thomas Börno; Andreas Dahl; et al.Michael LappeHans LehrachCayetano GonzalezGerard Armin Haupt; Gerard Joberty; Marcus Bantscheff; Holger Fröhlich; Henning Stehr; Michael-Ruth Schweiger; Axel Fischer; Martin Kerick; Stefan Thomas Börno; Andreas Dahl; et al. Heat shock protein 90 inhibitor differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics. *BMC Cancer* **2012**, *12*, 38-38, 10.1186/1471-2405-12-38.

35. Ganesh Raghu; Bram Rochwerger; Yuan Zhang; Carlos Cuello-García; Arata Azuma; Juergen Behr; Jan Brozek; Harold R. Collard; William Cunningham; Sakae Homma; et al.Takeshi JohkohFernando J. MartinezJeffrey MyersShandra L. ChungSuzanne Cooper. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. *Respiratory Care* **2020**, *65*, 2303-2312, 10.4187/respcare.04644.


40. Karuna M Das; Edward Y Lee; Rajvir Singh; Mushira A Enani; Khalid Al Dossari; Klaus Van Gorkom; Sven G Larsson; Ruth D Langer; Follow-up chest radiographic findings in patients with MERS-CoV after recovery. *Indian Journal of Radiology and Imaging* **2016**, *27*, 342-349, 10.4103/ijri.ijri_469_16.


44. Shih-Wen Li; T.-C. Yang; Lei Wan; Ying-Ju Lin; Fuu-Jen Tsai; Chien-Chen Lai; Cheng-Wen Lin; Correlation between TGF-β1 expression and proteomic profiling induced by severe acute respiratory syndrome coronavirus papain-like protease. *Proteomics* **2012**, *12*, 3193-3205, 10.1002/pmic.201200225.

46. Shih-Wen Li; T.-C. Yang; Lei Wan; Ying-Ju Lin; Fuu-Jen Tsai; Chien-Chen Lai; Cheng-Wen Lin; Correlation between TGF-β1 expression and proteomic profiling induced by severe acute respiratory syndrome coronavirus papain-like protease. *PROTEOMICS* **2012**, 12, 3193-3205, 10.1002/pmic.201200225.

**Keywords**

Idiopathic pulmonary fibrosis; heat shock proteins; Proteome; HSP90; HSP90 inhibitors; SARS-CoV-2; COVID-19; HSPome; antifibrotic

Retrieved from https://encyclopedia.pub/2154